Aggiornamento aziendale14 ott 2026ENMedincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)Medincell S.A.Medincell issuer announcements · Euronext
Aggiornamento aziendale13 ott 2026ENMedincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million LoanMedincell S.A.Medincell issuer announcements · Euronext
Aggiornamento aziendale9 ott 2026ENMedincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)Medincell S.A.Medincell issuer announcements · Euronext
Aggiornamento aziendale9 ott 2026ENMedincell Announces the Temporary Suspension of Trading in Its Shares on Euronext ParisMedincell S.A.Medincell issuer announcements · Euronext
Aggiornamento aziendale9 ott 2026ENMedincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pmMedincell S.A.Medincell issuer announcements · Euronext
Aggiornamento aziendale30 set 2026ENMedincell Extends Remote Voting Deadline for its Annual General Meeting Until 3:00 p.m. TodayMedincell S.A.Medincell issuer announcements · Euronext
Aggiornamento aziendale9 set 2026ENMedincell to Participate in Upcoming Investor ConferencesMedincell S.A.Medincell issuer announcements · Euronext
